zoledronic acid has been researched along with Local Neoplasm Recurrence in 34 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (14.71) | 29.6817 |
| 2010's | 24 (70.59) | 24.3611 |
| 2020's | 5 (14.71) | 2.80 |
| Authors | Studies |
|---|---|
| Avonto, I; Castella, B; D'Agostino, M; Giannotta, C; Grasso, M; Grimaldi, D; Kopecka, J; Larocca, A; Massaia, M; Riganti, C; Tripoli, E | 1 |
| Jukkola, A; Määttä, J; Mattila, PK; Petruk, N; Sandholm, J; Selander, KS; Siddiqui, A; Tadayon, S | 1 |
| Harada, H; Hayakawa, K; Katagiri, H; Miyazawa, K; Nagakura, H; Nakamura, N; Nozaki, M; Ogawa, H; Shikama, N; Uchida, N; Wada, H; Yamada, K | 1 |
| Aft, RL; Jallouk, AP; Paravastu, S; Weilbaecher, K | 1 |
| Hellig, J; Stevens, Z | 1 |
| Beelen, KJ; Bornebroek, M; Geijteman, ECT; Loef, M; Schweitzer, DH | 1 |
| Kuranishi, F; Ohno, T | 1 |
| Banys, M; Becker, S; Fehm, T; Gebauer, G; Hirnle, P; Huober, J; Janni, W; Kraemer, B; Krawczyk, N; Lueck, HJ; Solomayer, EF; Wackwitz, B; Wallwiener, D | 1 |
| Bouvet, M; Hayashi, K; Hiroshima, Y; Hoffman, RM; Kimura, H; Matsumoto, Y; Miwa, S; Sugimoto, N; Tsuchiya, H; Uehara, F; Yamamoto, M; Yamamoto, N; Yano, S; Zhang, Y | 1 |
| Anract, P; Bonnevialle, P; Di Marco, A; Fiorenza, F; Gouin, F; Rochwerger, AR; Rosset, P | 1 |
| Saad, F | 1 |
| Atkinson, C; Attia, J; Christie, D; Delahunt, B; Denham, JW; Diamond, T; Duchesne, G; Gogna, NK; Joseph, D; Kenny, L; Lamb, DS; Matthews, J; Oldmeadow, C; Spry, NA; Steigler, A; Tai, KH; Turner, S | 1 |
| Hanaoka, N; Kenji, E; Miyagi, R; Nishisho, T; Sairyo, K; Sakai, T; Takahashi, M; Toki, S; Yasui, N | 1 |
| Chien, MC; Hammoudeh, JA; Mascarenhas, L; Venkatramani, R | 1 |
| Aapro, M; Albert, US; Bergh, J; Body, JJ; Cameron, D; Clézardin, P; Coleman, RE; Conte, PF; Cortes, J; Costa, L; Di Leo, A; Diel, I; Dodwell, D; Ejlertsen, B; Gnant, M; Gray, R; Hadji, P; Harbeck, N; Holen, I; Kaufmann, M; Markopoulos, C; Martin, M; Powles, TJ; Santini, D; Smith, I; Thurlimann, B; Untch, M; Wilson, C | 1 |
| Bell, R; Cameron, DA; Coleman, RE; Gregory, WM; Howard, DR; Smye, SW; Twelves, CJ | 1 |
| Tannenbaum, S; Taxel, P; Varilla, V | 1 |
| Ceausu, I; Depypere, H; Lambrinoudaki, I; Mueck, A; Pérez-López, FR; Rees, M; Senturk, LM; Simoncini, T; Stevenson, JC; Stute, P; Trémollieres, FA; van der Schouw, YT | 1 |
| Bundred, N; Coleman, R; Davidson, N; de Boer, R; Eidtmann, H; Llombart-Cussac, A; Miller, J; Neven, P; Schenk, N; von Minckwitz, G | 1 |
| Anargyrou, K; Christoulas, D; Dimopoulos, MA; Gavriatopoulou, M; Kokkoris, P; Migkou, M; Terpos, E; Tsionos, K | 1 |
| Hering, F; Meler, A; Rodrigues, P | 1 |
| Athanasou, N; Balke, M; Campanacci, L; Gebert, C; Gibbons, M; Hogendoorn, P; Kroep, J; Picci, P; Taylor, R; Wass, J | 1 |
| Allegra, C; Drane, W; Gibbs, P; Marsh, Rde W; Reith, JD; Scarborough, M; Siddiqui, T; Whittaker, D; Zlotecki, R | 1 |
| Voelker, R | 1 |
| Chiu, CF; Lin, PH; Lu, YS | 1 |
| Body, JJ | 1 |
| Du, Y; Jiang, Y; Lu, J; Shao, Z; Yan, T; Yin, W; Zhou, L; Zhou, Q | 1 |
| Becker, S; Fehm, T; Gebauer, G; Hirnle, P; Huober, J; Janni, W; Krämer, B; Lück, HJ; Solomayer, EF; Wackwitz, B; Wallwiener, D | 1 |
| Blanchard, F; Charrier, C; Coipeau, P; Couillaud, S; Gouin, F; Heymann, D; Heymann, MF; Ory, B; Redini, F; Thiery, JP | 1 |
| Galanos, A; Katsouda, E; Kelekis, A; Mystakidou, K; Parpa, E; Vlahos, L | 1 |
| Gouin, F; Heymann, D; Ory, B; Rédini, F | 1 |
| Copeman, M; Gurney, H; Rosenthal, MA; Woo, H; Zingarelli, G | 1 |
| Friese, K; Janni, W; Rack, B; Schindlbeck, C; Sommer, H; Strobl, B | 1 |
5 review(s) available for zoledronic acid and Local Neoplasm Recurrence
| Article | Year |
|---|---|
Adjuvant bisphosphonates in early breast cancer: consensus guidance for clinical practice from a European Panel.
Topics: Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Chemotherapy, Adjuvant; Clodronic Acid; Consensus; Diphosphonates; Europe; Female; Humans; Imidazoles; Neoplasm Recurrence, Local; Osteoporosis; Surveys and Questionnaires; Zoledronic Acid | 2016 |
Celecoxib With or Without Zoledronic Acid for Hormone-Naïve Prostate Cancer: Survival Results From STAMPEDE (NCT00268476).
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Density Conservation Agents; Celecoxib; Clinical Trials as Topic; Cyclooxygenase 2 Inhibitors; Diphosphonates; Humans; Imidazoles; Male; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Prostatic Neoplasms; Retreatment; Treatment Outcome; Zoledronic Acid | 2016 |
Osteoporosis management in patients with breast cancer: EMAS position statement.
Topics: Aromatase Inhibitors; Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Female; Fractures, Bone; Humans; Imidazoles; Neoplasm Recurrence, Local; Osteoporosis; Premenopause; Zoledronic Acid | 2017 |
New developments for treatment and prevention of bone metastases.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bone and Bones; Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Clinical Trials as Topic; Denosumab; Diphosphonates; Female; Humans; Imidazoles; Jaw; Male; Neoplasm Recurrence, Local; Osteonecrosis; Prostatic Neoplasms; RANK Ligand; Zoledronic Acid | 2011 |
The efficacy of zoledronic acid in breast cancer adjuvant therapy: a meta-analysis of randomised controlled trials.
Topics: Antineoplastic Agents; Bone Density Conservation Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Diphosphonates; Disease-Free Survival; Female; Humans; Imidazoles; Neoplasm Recurrence, Local; Randomized Controlled Trials as Topic; Survival Analysis; Zoledronic Acid | 2012 |
10 trial(s) available for zoledronic acid and Local Neoplasm Recurrence
| Article | Year |
|---|---|
A phase II study of palliative radiotherapy combined with zoledronic acid hydrate for metastatic bone tumour from renal cell carcinoma.
Topics: Aged; Aged, 80 and over; Bone Neoplasms; Carcinoma, Renal Cell; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Palliative Care; Treatment Outcome; Zoledronic Acid | 2021 |
Long-term outcome of (neo)adjuvant zoledronic acid therapy in locally advanced breast cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Breast Neoplasms; Female; Humans; Imidazoles; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Treatment Outcome; Zoledronic Acid | 2021 |
Influence of zoledronic acid on disseminated tumor cells in bone marrow and survival: results of a prospective clinical trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Bone Marrow; Breast Neoplasms; Chemoradiotherapy, Adjuvant; Diphosphonates; Female; Follow-Up Studies; Humans; Imidazoles; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Time Factors; Tumor Burden; Zoledronic Acid | 2013 |
Adjuvant treatment with zoledronic acid after extensive curettage for giant cell tumours of bone.
Topics: Adult; Aged; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Female; Giant Cell Tumor of Bone; Humans; Imidazoles; Male; Middle Aged; Neoplasm Recurrence, Local; Young Adult; Zoledronic Acid | 2014 |
Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): an open-label, randomised, phase 3 factorial
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Brachytherapy; Combined Modality Therapy; Diphosphonates; Disease-Free Survival; Drug Administration Schedule; Follow-Up Studies; Humans; Imidazoles; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Prostate-Specific Antigen; Prostatic Neoplasms; Survival Analysis; Treatment Outcome; Zoledronic Acid | 2014 |
Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Bone Resorption; Breast Neoplasms; Chemotherapy, Adjuvant; Diphosphonates; Drug Therapy, Combination; Female; Humans; Imidazoles; Letrozole; Neoplasm Recurrence, Local; Neoplasm Staging; Nitriles; Postmenopause; Survival Rate; Time Factors; Treatment Outcome; Triazoles; Zoledronic Acid | 2010 |
Titration of dosage for the protective effect of zoledronic acid on bone loss in patients submitted to androgen deprivation therapy due to prostate cancer: a prospective open-label study.
Topics: Absorptiometry, Photon; Adenocarcinoma; Aged; Androgen Antagonists; Bone Density; Bone Density Conservation Agents; Brazil; Chemotherapy, Adjuvant; Diphosphonates; Drug Administration Schedule; Gonadotropin-Releasing Hormone; Humans; Imidazoles; Infusions, Intravenous; Lumbar Vertebrae; Male; Neoplasm Recurrence, Local; Osteoporosis; Prospective Studies; Prostatectomy; Prostatic Neoplasms; Time Factors; Treatment Outcome; Zoledronic Acid | 2010 |
Influence of zoledronic acid on disseminated tumor cells in primary breast cancer patients.
Topics: Adult; Aged; Antineoplastic Agents; Arthralgia; Bone Marrow Cells; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Middle Aged; Neoplasm Recurrence, Local; Neoplastic Cells, Circulating; Treatment Outcome; Zoledronic Acid | 2012 |
Randomized, open label, prospective study on the effect of zoledronic acid on the prevention of bone metastases in patients with recurrent solid tumors that did not present with bone metastases at baseline.
Topics: Aged; Bone Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasms; Prospective Studies; Treatment Outcome; Zoledronic Acid | 2005 |
[Efficacy of zoledronate in treating persisting isolated tumor cells in bone marrow in patients with breast cancer. A phase II pilot study].
Topics: Adult; Aged; Antineoplastic Agents; Bone Density Conservation Agents; Bone Marrow; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Combined Modality Therapy; Diphosphonates; Female; Humans; Imidazoles; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Hormone-Dependent; Pain; Pilot Projects; Prognosis; Zoledronic Acid | 2008 |
19 other study(ies) available for zoledronic acid and Local Neoplasm Recurrence
| Article | Year |
|---|---|
Immune dysfunctions affecting bone marrow Vγ9Vδ2 T cells in multiple myeloma: Role of immune checkpoints and disease status.
Topics: Bone Marrow; Hepatitis A Virus Cellular Receptor 2; Humans; Multiple Myeloma; Neoplasm Recurrence, Local; Programmed Cell Death 1 Receptor; Receptors, Antigen, T-Cell; T-Lymphocytes; Tumor Microenvironment; Zoledronic Acid | 2022 |
CD73 regulates zoledronate-induced lymphocyte infiltration in triple-negative breast cancer tumors and lung metastases.
Topics: Animals; Humans; Imidazoles; Lung Neoplasms; Mice; Neoplasm Recurrence, Local; T-Lymphocytes; Triple Negative Breast Neoplasms; Zoledronic Acid | 2023 |
Breast cancer therapy and bone.
Topics: Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Female; Fractures, Bone; Humans; Neoplasm Recurrence, Local; Zoledronic Acid | 2022 |
[Relapse of chronic inflammatory demyelinating polyneuropathy following treatment with zoledronic acid].
Topics: Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Middle Aged; Neoplasm Recurrence, Local; Polyradiculoneuropathy, Chronic Inflammatory Demyelinating; Zoledronic Acid | 2017 |
Eradication of breast cancer with bone metastasis by autologous formalin-fixed tumor vaccine (AFTV) combined with palliative radiation therapy and adjuvant chemotherapy: a case report.
Topics: Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Autoantigens; Bone Neoplasms; Breast Neoplasms; Cancer Vaccines; Chemotherapy, Adjuvant; Combined Modality Therapy; Cyclophosphamide; Diphosphonates; Epirubicin; Female; Fixatives; Fluorouracil; Formaldehyde; Humans; Imidazoles; Magnetic Resonance Imaging; Mastectomy; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Prognosis; Radiotherapy Dosage; Tomography, Emission-Computed, Single-Photon; Triazoles; Zoledronic Acid | 2013 |
Fluorescence-guided surgery of prostate cancer bone metastasis.
Topics: Adenocarcinoma; Animals; Bone Density Conservation Agents; Bone Neoplasms; Cell Line, Tumor; Diphosphonates; Disease Models, Animal; Disease-Free Survival; Green Fluorescent Proteins; Humans; Imidazoles; Luminescent Proteins; Lymphatic Metastasis; Male; Mice, Nude; Neoplasm Recurrence, Local; Neoplasm, Residual; Optical Imaging; Prostatic Neoplasms; Red Fluorescent Protein; Zoledronic Acid | 2014 |
Role of bisphosphonates in non-metastatic prostate cancer.
Topics: Adenocarcinoma; Androgen Antagonists; Brachytherapy; Diphosphonates; Humans; Imidazoles; Male; Neoplasm Recurrence, Local; Prostatic Neoplasms; Zoledronic Acid | 2014 |
Local administration of zoledronic acid for giant cell tumor of bone.
Topics: Administration, Topical; Adult; Aged; Bone Density Conservation Agents; Bone Neoplasms; Bone Substitutes; Combined Modality Therapy; Diphosphonates; Female; Giant Cell Tumor of Bone; Humans; Imidazoles; Male; Middle Aged; Neoplasm Recurrence, Local; Young Adult; Zoledronic Acid | 2015 |
Zoledronic Acid for the Treatment of Children With Refractory Central Giant Cell Granuloma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Child; Child, Preschool; Diphosphonates; Drug Resistance, Neoplasm; Female; Granuloma, Giant Cell; Humans; Imidazoles; Infant; Male; Neoplasm Recurrence, Local; Prognosis; Zoledronic Acid | 2015 |
Characterizing and quantifying the effects of breast cancer therapy using mathematical modeling.
Topics: Antineoplastic Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Diphosphonates; Disease-Free Survival; Female; Humans; Imidazoles; Models, Theoretical; Neoplasm Recurrence, Local; Receptors, Estrogen; Zoledronic Acid | 2016 |
Metastatic Inflammatory Breast Cancer Associated With Multicentric Reticulohistiocytosis Successfully Treated With Zoledronic Acid.
Topics: Diphosphonates; Female; Histiocytosis, Non-Langerhans-Cell; Humans; Imidazoles; Inflammatory Breast Neoplasms; Middle Aged; Neoplasm Recurrence, Local; Zoledronic Acid | 2016 |
Increased bone mineral density in a subset of patients with relapsed multiple myeloma who received the combination of bortezomib, dexamethasone and zoledronic acid.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Density; Bone Density Conservation Agents; Boronic Acids; Bortezomib; Dexamethasone; Diphosphonates; Drug Therapy, Combination; Female; Humans; Imidazoles; Male; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines; Survival Rate; Treatment Outcome; Zoledronic Acid | 2010 |
Bisphosphonate treatment of aggressive primary, recurrent and metastatic Giant Cell Tumour of Bone.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Bone Neoplasms; Bone Resorption; Diphosphonates; Female; Giant Cell Tumor of Bone; Humans; Imidazoles; Lung Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Osteoclasts; Treatment Outcome; Tumor Cells, Cultured; Young Adult; Zoledronic Acid | 2010 |
Effective salvage treatment of recurrent Ewing sarcoma utilizing chemotherapy and zoledronic acid.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Drug Therapy, Combination; Humans; Imidazoles; Male; Neoplasm Recurrence, Local; Remission Induction; Salvage Therapy; Sarcoma, Ewing; Treatment Outcome; Zoledronic Acid | 2010 |
"Disappointing" trial results offer hope for older women with breast cancer.
Topics: Aged; Bone Density Conservation Agents; Breast Neoplasms; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Diphosphonates; Disease Progression; Disease-Free Survival; Estrogens; Female; Humans; Imidazoles; Menopause; Neoplasm Recurrence, Local; Treatment Failure; Zoledronic Acid | 2011 |
Cisplatin as an active treatment in zoledronate-refractory hypercalcemia.
Topics: Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Cisplatin; Diphosphonates; Female; Fluorouracil; Humans; Hypercalcemia; Imidazoles; Leucovorin; Middle Aged; Neoplasm Recurrence, Local; Treatment Failure; Vinblastine; Vinorelbine; Zoledronic Acid | 2011 |
Enhanced tumor regression and tissue repair when zoledronic acid is combined with ifosfamide in rat osteosarcoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bone Remodeling; Caspases; Cell Line, Tumor; Cell Proliferation; Diphosphonates; Fibrosis; Ifosfamide; Imidazoles; Male; Necrosis; Neoplasm Metastasis; Neoplasm Recurrence, Local; Osteoblasts; Osteogenesis; Osteosarcoma; Rats; Rats, Sprague-Dawley; S Phase; Survival Rate; Tibia; Time Factors; Tomography, X-Ray Computed; Treatment Outcome; Zoledronic Acid | 2005 |
Zoledronic acid slows down rat primary chondrosarcoma development, recurrent tumor progression after intralesional curretage and increases overall survival.
Topics: Animals; Antineoplastic Agents; Apoptosis; Bone Density Conservation Agents; Caspase 1; Caspase 3; Caspases; Cell Cycle; Cell Proliferation; Chemotherapy, Adjuvant; Chondrosarcoma; Curettage; Diphosphonates; Disease Progression; Imidazoles; Male; Neoplasm Recurrence, Local; Rats; Rats, Sprague-Dawley; Survival Analysis; Zoledronic Acid | 2006 |
Death of a clinical trial: a speculative inclusion criterion gone wrong.
Topics: Antineoplastic Agents; Australia; Chemotherapy, Adjuvant; Diphosphonates; Docetaxel; Humans; Imidazoles; Male; Multicenter Studies as Topic; Neoplasm Recurrence, Local; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Reverse Transcriptase Polymerase Chain Reaction; Taxoids; Zoledronic Acid | 2007 |